Rashmi Kushwaha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rashmi Kushwaha has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Anurag Singh
Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India
15 shared publicationsShailendra Prasad Verma
Department of Clinical Hematology, King George's Medical University, Lucknow, India
9 shared publications- Shailendra Prasad Verma
Department of Clinical Hematology, King George’s Medical University, Lucknow, India
7 shared publications Shalini Rawat
Department of Pathology, King George Medical University, Lucknow, Uttar Pradesh, India
7 shared publicationsUma Shankar Singh
Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
7 shared publications- Uma Shankar Singh
Department of Pathology, King George‘s Medical University, Lucknow, India
5 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Springer Nature in BMC Cancer
miR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling
Background: microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology: We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated miRNAs, and miR-451a was subsequently validated using quantitative real-time PCR (qRT-PCR). Result: The study found that miR-451a was significantly elevated in CML cases compared to controls out of all 450–500 identified miRs. Receiver operating characteristic (ROC) analysis demonstrated moderate predictive performance (AUROC = 0.655), with 76.6% sensitivity and 53.2% specificity at a defined threshold (ΔCt ≥ 1.270). Logistic regression analysis confirmed miR-451a as an independent predictor, with a 16.5% increase in disease odds for each unit (OR = 1.165, p = 0.001). These findings suggest that miR-451a may function as an independent predictor for CML and a valuable molecular marker for disease risk and progression. Conclusion: miR-451a is markedly overexpressed in the peripheral blood of patients with newly diagnosed CML and demonstrates moderate efficacy as a candidate biomarker. Its integration into a multi-marker panel may enhance diagnostic sensitivity and specificity, reinforcing its role in advancing precision medicine approaches in CML.
- 27 August 2026
- Published by Springer Nature in BMC Cancer
Open AccessmiR-451a is a differentially expressed blood-based microRNA in newly diagnosed CML identified by high-throughput profiling
Background: microRNAs (miRNAs) are emerging as promising biomarkers in hematological malignancies due to their stability in blood. This study aimed to investigate the differential expression of miRNAs in chronic myeloid leukemia (CML) and evaluate the potential of miR-451a as a candidate whole-blood miRNA marker. Methodology: We collected whole blood samples from 77 newly diagnosed CML patients before TKI therapy and 77 healthy controls. A subset of samples underwent miRNA sequencing to identify dysregulated miRNAs, and miR-451a was subsequently validated using quantitative real-time PCR (qRT-PCR). Result: The study found that miR-451a was significantly elevated in CML cases compared to controls out of all 450–500 identified miRs. Receiver operating characteristic (ROC) analysis demonstrated moderate predictive performance (AUROC = 0.655), with 76.6% sensitivity and 53.2% specificity at a defined threshold (ΔCt ≥ 1.270). Logistic regression analysis confirmed miR-451a as an independent predictor, with a 16.5% increase in disease odds for each unit (OR = 1.165, p = 0.001). These findings suggest that miR-451a may function as an independent predictor for CML and a valuable molecular marker for disease risk and progression. Conclusion: miR-451a is markedly overexpressed in the peripheral blood of patients with newly diagnosed CML and demonstrates moderate efficacy as a candidate biomarker. Its integration into a multi-marker panel may enhance diagnostic sensitivity and specificity, reinforcing its role in advancing precision medicine approaches in CML.
- 27 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (6) , 2187-2207
Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia
- 27 August 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (6) , 2187-2207
Indian Consensus Guidelines for the Diagnosis and Management of Aplastic Anemia
- Open Access
XRRA1 acts as a molecular brake on radiation-induced DNA damage signaling and immunogenic cell death in tumor cells
Radiotherapy kills cancer cells by inducing DNA damage, but adaptive responses that buffer injury and limit immunogenic signaling remain incompletely understood. Although ionizing radiation can activate cytosolic DNA sensing and immunogenic cell death, the tumor-intrinsic regulators linking these processes to radioresistance are not well defined. Here, we show that XRRA1 is a stress-adaptive determinant of radioresponse identified by integrating discovery proteomics into chronic myeloid leukemia with clinical tissue validation and functional studies across multiple tumor models. In peripheral-blood proteomes, XRRA1 was quantitatively reduced in chronic myeloid leukemia yet associated with a favorable prognosis and with networks enriched for RNA regulation, apoptosis, and DNA-repair biology. In human biopsy specimens, XRRA1 protein abundance was increased in radiation-exposed tissues, and in cultured cells, ionizing radiation induced XRRA1 more strongly and persistently in normal cells than in cancer cells. Silencing XRRA1 had little effect on basal growth but markedly enhanced radiation-induced loss of viability, apoptosis, spheroid disruption, and clonogenic failure, while increasing γH2AX- and DNA-PK-associated damage signaling and linking XRRA1 to non-homologous end joining factors. XRRA1 depletion also amplified cGAS-STING-TBK1-IRF3 activation, interferon-stimulated gene expression, extracellular ATP release, and cell-surface calreticulin exposure. These findings identify XRRA1 as a molecular brake that limits the conversion of radiation-induced DNA damage into immunogenic stress responses. XRRA1, therefore, represents a candidate biomarker of radioadaptive stress and a potential target for radiosensitization and radiotherapy-immunotherapy combinations.
Open AccessXRRA1 acts as a molecular brake on radiation-induced DNA damage signaling and immunogenic cell death in tumor cells
Radiotherapy kills cancer cells by inducing DNA damage, but adaptive responses that buffer injury and limit immunogenic signaling remain incompletely understood. Although ionizing radiation can activate cytosolic DNA sensing and immunogenic cell death, the tumor-intrinsic regulators linking these processes to radioresistance are not well defined. Here, we show that XRRA1 is a stress-adaptive determinant of radioresponse identified by integrating discovery proteomics into chronic myeloid leukemia with clinical tissue validation and functional studies across multiple tumor models. In peripheral-blood proteomes, XRRA1 was quantitatively reduced in chronic myeloid leukemia yet associated with a favorable prognosis and with networks enriched for RNA regulation, apoptosis, and DNA-repair biology. In human biopsy specimens, XRRA1 protein abundance was increased in radiation-exposed tissues, and in cultured cells, ionizing radiation induced XRRA1 more strongly and persistently in normal cells than in cancer cells. Silencing XRRA1 had little effect on basal growth but markedly enhanced radiation-induced loss of viability, apoptosis, spheroid disruption, and clonogenic failure, while increasing γH2AX- and DNA-PK-associated damage signaling and linking XRRA1 to non-homologous end joining factors. XRRA1 depletion also amplified cGAS-STING-TBK1-IRF3 activation, interferon-stimulated gene expression, extracellular ATP release, and cell-surface calreticulin exposure. These findings identify XRRA1 as a molecular brake that limits the conversion of radiation-induced DNA damage into immunogenic stress responses. XRRA1, therefore, represents a candidate biomarker of radioadaptive stress and a potential target for radiosensitization and radiotherapy-immunotherapy combinations.
- 1 April 2026
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 74 (2) , 103585
Role of IGF2BP3 as a prognostic biomarker in chronic myeloid leukemia progression and disease stratification
- 1 April 2026
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 74 (2) , 103585
Role of IGF2BP3 as a prognostic biomarker in chronic myeloid leukemia progression and disease stratification
- Open Access
- 8 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2268
High-Resolution Genetic Profiling of Hb J-Meerut and Other Hemoglobin Variants in the Tharu Population via HPLC and DNA Sequencing
Background/Objectives: Hemoglobinopathies, including thalassemia and sickle cell disease, are among the most common inherited disorders worldwide. This study aimed to profile hemoglobin variants in the Tharu community of Lakhimpur Kheri, Uttar Pradesh, with particular focus on the rare variant Hb J-Meerut [α 120 (H3) Ala→Glu (α1)]. Methods: A cross-sectional study was conducted during a community health camp in February 2024. Peripheral blood samples were collected from 505 individuals, of which 445 were analyzed using complete blood count (CBC) and high-performance liquid chromatography (HPLC). Suspected variants were confirmed by Sanger sequencing. Results: Hemoglobinopathies were identified in nearly one-fifth of participants. The major variants detected were sickle cell trait, β-thalassemia trait, and Hb J-Meerut. Sequencing confirmed Hb J-Meerut in the majority of suspected cases. HPLC profiles showed clear differences between groups, supporting its role as a reliable screening tool. Conclusions: Community-based screening combining HPLC and sequencing provides an effective approach for identifying both common and rare hemoglobin variants. Early detection of silent carriers such as Hb J-Meerut is essential for targeted genetic counseling and preventive strategies in high-risk populations.
- 8 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (17) , 2268
Open AccessHigh-Resolution Genetic Profiling of Hb J-Meerut and Other Hemoglobin Variants in the Tharu Population via HPLC and DNA Sequencing
Background/Objectives: Hemoglobinopathies, including thalassemia and sickle cell disease, are among the most common inherited disorders worldwide. This study aimed to profile hemoglobin variants in the Tharu community of Lakhimpur Kheri, Uttar Pradesh, with particular focus on the rare variant Hb J-Meerut [α 120 (H3) Ala→Glu (α1)]. Methods: A cross-sectional study was conducted during a community health camp in February 2024. Peripheral blood samples were collected from 505 individuals, of which 445 were analyzed using complete blood count (CBC) and high-performance liquid chromatography (HPLC). Suspected variants were confirmed by Sanger sequencing. Results: Hemoglobinopathies were identified in nearly one-fifth of participants. The major variants detected were sickle cell trait, β-thalassemia trait, and Hb J-Meerut. Sequencing confirmed Hb J-Meerut in the majority of suspected cases. HPLC profiles showed clear differences between groups, supporting its role as a reliable screening tool. Conclusions: Community-based screening combining HPLC and sequencing provides an effective approach for identifying both common and rare hemoglobin variants. Early detection of silent carriers such as Hb J-Meerut is essential for targeted genetic counseling and preventive strategies in high-risk populations.
- Open Access
- 27 January 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 4 (1)
Long bone fracture in a child with haemophilia- surgical management under factor coverage: A case report and literature review
- 27 January 2025
- Published by Elsevier in Journal of Orthopaedic Reports
- Vol. 4 (1)
Open AccessLong bone fracture in a child with haemophilia- surgical management under factor coverage: A case report and literature review
- Open Access
AI-Powered Exploration of IGF2BP3 as a Prognostic Biomarker in Chronic Myeloid Leukemia Progression and Disease Stratification
Background: Chronic Myeloid Leukemia (CML) progresses through chronic, accelerated, and blast crisis phases, making disease stratification and therapeutic response prediction challenging. IGF2BP3 (Insulin-like Growth Factor 2 mRNA Binding Protein 3) has emerged as a potential prognostic biomarker due to its involvement in RNA stability and oncogenic pathways. Methods: This study employed a multi-platform approach, including immunohistochemistry (IHC), ELISA, qRT-PCR, and Western blotting, to evaluate IGF2BP3 expression in 121 CML patient samples across disease stages. Advanced artificial intelligence (ChatGPT 4.0) and statistical tools (R-Studio) were utilized to analyze correlations between IGF2BP3 levels, clinical parameters, and treatment responses. Results: IGF2BP3 expression progressively increased from the chronic to the blast crisis phase, correlating with disease severity and resistance to therapy. IHC staining intensity and serum levels of IGF2BP3 were highest in the blast crisis phase, confirmed by qRT-PCR and Western blotting. AI-powered regression analysis revealed a strong correlation between IGF2BP3 levels, P210 translocation percentages, and blast counts. Non-responders to therapy exhibited significantly elevated IGF2BP3 levels, underscoring its potential as a marker for treatment resistance. Conclusions: IGF2BP3 is a reliable biomarker for CML disease progression, therapeutic resistance, and patient stratification. Targeting IGF2BP3 may offer novel therapeutic opportunities, particularly in advanced disease stages. This study demonstrates the utility of integrating AI in biomarker research to enhance precision and actionable insights.
Open AccessAI-Powered Exploration of IGF2BP3 as a Prognostic Biomarker in Chronic Myeloid Leukemia Progression and Disease Stratification
Background: Chronic Myeloid Leukemia (CML) progresses through chronic, accelerated, and blast crisis phases, making disease stratification and therapeutic response prediction challenging. IGF2BP3 (Insulin-like Growth Factor 2 mRNA Binding Protein 3) has emerged as a potential prognostic biomarker due to its involvement in RNA stability and oncogenic pathways. Methods: This study employed a multi-platform approach, including immunohistochemistry (IHC), ELISA, qRT-PCR, and Western blotting, to evaluate IGF2BP3 expression in 121 CML patient samples across disease stages. Advanced artificial intelligence (ChatGPT 4.0) and statistical tools (R-Studio) were utilized to analyze correlations between IGF2BP3 levels, clinical parameters, and treatment responses. Results: IGF2BP3 expression progressively increased from the chronic to the blast crisis phase, correlating with disease severity and resistance to therapy. IHC staining intensity and serum levels of IGF2BP3 were highest in the blast crisis phase, confirmed by qRT-PCR and Western blotting. AI-powered regression analysis revealed a strong correlation between IGF2BP3 levels, P210 translocation percentages, and blast counts. Non-responders to therapy exhibited significantly elevated IGF2BP3 levels, underscoring its potential as a marker for treatment resistance. Conclusions: IGF2BP3 is a reliable biomarker for CML disease progression, therapeutic resistance, and patient stratification. Targeting IGF2BP3 may offer novel therapeutic opportunities, particularly in advanced disease stages. This study demonstrates the utility of integrating AI in biomarker research to enhance precision and actionable insights.
- Open Access
- 23 October 2024
- Published by Wolters Kluwer Health in Annals of African Medicine
- Vol. 24 (1) , 194-197
An Uncommon Case of Plasmodium vivax Malaria with Disseminated Intravascular Coagulation: Rare Case Report with Review of Literature
Malaria is a severe health issue in India despite government efforts. Malaria has many complications, some of which can be life-threatening. Disseminated intravascular coagulation (DIC) is a prominent malaria complication, besides renal failure, cerebral malaria, pulmonary edema, and anemia. We report a young man with Plasmodium vivax malaria who developed septic shock due to DIC. A 25-year-old male had a fever, abdominal pain, vomiting, and nausea for 5 days. On clinical examination, the patient was in distress and had a fever of 102.6°F with a blood pressure of 86/46 mmHg. A complete blood count revealed anemia, leukocytopenia, and severe thrombocytopenia. Peripheral blood smear findings showed a P. vivax parasite in red blood cells with the presence of a few schistocytes. Further coagulation tests showed raised prothrombin, partial thromboplastin time, and d-dimer. DIC and septic shock required critical care unit admission. Conservative treatment with artesunate and lumefantrine completely cured him. This unusual case shows that P. vivax causes severe malaria and its morbid consequences. It stresses early diagnosis and treatment to prevent mortality and morbidity.
- 23 October 2024
- Published by Wolters Kluwer Health in Annals of African Medicine
- Vol. 24 (1) , 194-197
Open AccessAn Uncommon Case of Plasmodium vivax Malaria with Disseminated Intravascular Coagulation: Rare Case Report with Review of Literature
Malaria is a severe health issue in India despite government efforts. Malaria has many complications, some of which can be life-threatening. Disseminated intravascular coagulation (DIC) is a prominent malaria complication, besides renal failure, cerebral malaria, pulmonary edema, and anemia. We report a young man with Plasmodium vivax malaria who developed septic shock due to DIC. A 25-year-old male had a fever, abdominal pain, vomiting, and nausea for 5 days. On clinical examination, the patient was in distress and had a fever of 102.6°F with a blood pressure of 86/46 mmHg. A complete blood count revealed anemia, leukocytopenia, and severe thrombocytopenia. Peripheral blood smear findings showed a P. vivax parasite in red blood cells with the presence of a few schistocytes. Further coagulation tests showed raised prothrombin, partial thromboplastin time, and d-dimer. DIC and septic shock required critical care unit admission. Conservative treatment with artesunate and lumefantrine completely cured him. This unusual case shows that P. vivax causes severe malaria and its morbid consequences. It stresses early diagnosis and treatment to prevent mortality and morbidity.
- Open Access
- 23 October 2024
- Published by Wolters Kluwer Health in Annals of African Medicine
- Vol. 24 (1) , 68-74
Correlation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy
Background: Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-β1 at diagnosis and 3 months postdasatinib therapy. Materials and Methods: The Pathology and Clinical Haematology Departments at King George’s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-β1. Results: T-regulatory cells, CTLA-4, and TGF-β1 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-β1 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders. Conclusions: The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-β1 levels.
- 23 October 2024
- Published by Wolters Kluwer Health in Annals of African Medicine
- Vol. 24 (1) , 68-74
Open AccessCorrelation of T Regulatory Cells, Cytotoxic T-lymphocyte-associated Antigen 4, and Transforming Growth Factor-β1 with Treatment Response in Patients with Chronic Myeloid Leukemia Receiving Dasatinib Therapy
Background: Tyrosine kinase inhibitors improve chronic myeloid leukemia (CML) outcomes. Dasatinib inhibits breakpoint cluster region-Abelson 1 proto-oncogene tyrosine kinase better than imatinib in CML. T-regulatory cells prevent autoimmune diseases and aberrant immune responses by reducing oncoprotein antigen reactivity. They also reduce self-antigen-induced immune responses to maintain peripheral tolerance. In this study, T-regulatory cells in peripheral blood of chronic myeloid leukemia-chronic phase patients were measured, together with serum levels of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and transforming growth factor (TGF)-β1 at diagnosis and 3 months postdasatinib therapy. Materials and Methods: The Pathology and Clinical Haematology Departments at King George’s Medical University, Lucknow, India, conducted this prospective analytical study. Forty CML-chronic patients and 10 healthy controls were analyzed. Flow cytometry was used to determine T-regulatory cell percentage in peripheral blood mononuclear cells of newly diagnosed CML patients before and after 3 months of dasatinib treatment; ELISA was used to measure serum levels of CTLA-4 and TGF-β1. Results: T-regulatory cells, CTLA-4, and TGF-β1 significantly decreased in CML-chronic phase patients after 3 months of dasatinib therapy compared to the initial diagnosis. No significant change in T-regulatory cell, CTLA-4, or TGF-β1 percentages were seen between responders and poor responders. However, responders had a lower percentage of T-regulatory cells than suboptimal responders. Conclusions: The study concluded that dasatinib treatment improved response in CML patients with decreased Treg cells. Dasatinib reduces Treg-mediated immunological suppression, reducing CTLA-4 and TGF-β1 levels.